Brind.

Ironwood Pharmaceuticals was classified in the Zacks Medical - Drugs industry in August 2025.

1 report, 1 independent Updated Aug 7

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Ironwood Pharmaceuticals

Keep exploring

The entities involved

Ironwood Pharmaceuticals
company in Cambridge, United States
- Analyst upgraded Ironwood Pharmaceuticals to 'hold' rating, concurrent with insider selling disclosures filed with the SEC.Sat 10:54

Related events

Ironwood Pharmaceuticals listed its shares on the electronic stock exchange on September 8, 2026.Sep 8

Coverage

Newest first; wire copies grouped

Aug 7ZacksIronwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a